News

Your Voice

Dosing inconsistencies and other questions about emergency contraception

The patient, a 13-year-old girl, was concerned about the development of a very itchy, painful, papular rash on her hands and feet. She had been previously well and had no history of illness other than a minor upper respiratory tract infection 2 weeks earlier. The distribution of lesions and the severe pruritus initially suggested scabies, which was treated with 5% permethrin cream. The rash did not improve with applications of this medication, however, and the patient returned the following day for care. She had no oral lesions but complained of mildly painful, nonswollen joints.

The FDA recently approved Vusion, an ointment specifically formulated for the treatment of diaper dermatitis complicated by Candida in infants 4 weeks and older. Manufactured by Barrier Therapeutics, Vusion is, according to Barrier, the only prescription product approved for the treatment of diaper rash in the US.

A team of researchers has declared a condition known as eosinophilic esophagitis (EE) as an emerging health concern for children that could cause a host of lifelong problems. This severe, chronic condition has often been misdiagnosed and has been recognized increasingly in the US, Europe, Canada, and Japan in the past few years.

The Food and Drug Administration (FDA) this month approved the use of 40-mg, 50-mg, and 60-mg Medadate CD CII (methylphenidate HCI, manufactured by UCB) Extended-Release Capsules for the treatment of attention deficit hyperactivity disorder (ADHD).